Kairos Pharma, Ltd.
KAPA
$0.85
-$0.01-1.05%
AMEX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.85% | 24.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.44% | 15.01% | |||
| Operating Income | 1.44% | -15.01% | |||
| Income Before Tax | 1.69% | -12.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.69% | -12.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.69% | -12.68% | |||
| EBIT | 1.44% | -15.01% | |||
| EBITDA | 1.48% | -15.50% | |||
| EPS Basic | 16.22% | -3.90% | |||
| Normalized Basic EPS | 16.28% | -3.82% | |||
| EPS Diluted | 16.22% | -3.90% | |||
| Normalized Diluted EPS | 16.28% | -3.82% | |||
| Average Basic Shares Outstanding | 17.39% | 8.42% | |||
| Average Diluted Shares Outstanding | 17.39% | 8.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||